Gedeon Richter Further Extends Women's Health BusinessNovember 2010 | Industry Trend Analysis
BMI View: Despite stronger growth potential in emerging pharmaceutical markets, drugmakers based in developing countries are set to increase their presence in developed states. In the case of Gedeon Richter, this will enable it to exploit the superior penetration of patented and higher value drugs in more advanced markets.BMI believes that Gedeon Richter's acquisition of Grünenthal's oral contraceptive portfolio is beneficial for both companies. However, we are concerned that the value of the transaction is considerably higher than the potential revenue that could currently be generated from the acquired portfolio. In order to ensure a return on its investment, it will be essential for Gedeon Richter fully to exploit its expertise in women's health.
To read the full article, please choose one of the following options: